X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1193) 1193
life sciences & biomedicine (1084) 1084
humans (972) 972
animals (811) 811
bridged bicyclo compounds, heterocyclic - pharmacology (695) 695
male (615) 615
bridged bicyclo compounds, heterocyclic - therapeutic use (545) 545
pharmacology & pharmacy (421) 421
female (405) 405
mice (328) 328
rats (303) 303
oncology (239) 239
bridged bicyclo compounds, heterocyclic - administration & dosage (231) 231
dose-response relationship, drug (212) 212
middle aged (199) 199
adult (198) 198
cell line, tumor (197) 197
bridged bicyclo compounds, heterocyclic (178) 178
aged (165) 165
bridged bicyclo compounds, heterocyclic - chemistry (163) 163
neurosciences (163) 163
apoptosis (161) 161
neurosciences & neurology (154) 154
apoptosis - drug effects (143) 143
sulfonamides - therapeutic use (142) 142
cancer (139) 139
antineoplastic agents - pharmacology (138) 138
antineoplastic agents - therapeutic use (136) 136
bridged bicyclo compounds, heterocyclic - adverse effects (132) 132
disease models, animal (130) 130
rats, sprague-dawley (130) 130
analysis (123) 123
treatment outcome (123) 123
bridged bicyclo compounds, heterocyclic - pharmacokinetics (120) 120
hematology (116) 116
cell biology (114) 114
sulfonamides - pharmacology (110) 110
proteins (109) 109
biochemistry & molecular biology (108) 108
research (103) 103
proto-oncogene proteins c-bcl-2 - antagonists & inhibitors (97) 97
abridged index medicus (95) 95
science & technology - other topics (95) 95
care and treatment (94) 94
double-blind method (92) 92
research article (89) 89
antineoplastic combined chemotherapy protocols - therapeutic use (87) 87
cell proliferation - drug effects (85) 85
leukemia, lymphocytic, chronic, b-cell - drug therapy (84) 84
drug therapy (82) 82
leukemia (82) 82
health aspects (81) 81
mice, inbred c57bl (78) 78
time factors (78) 78
amino acids - pharmacology (77) 77
chemotherapy (77) 77
multidisciplinary sciences (76) 76
in vitro techniques (75) 75
kinases (75) 75
pyridines - pharmacology (75) 75
chemistry (74) 74
bridged bicyclo compounds, heterocyclic - metabolism (71) 71
pharmacology/toxicology (71) 71
proto-oncogene proteins c-bcl-2 - metabolism (69) 69
rats, wistar (69) 69
rodents (69) 69
clinical trials as topic (68) 68
psychiatry (68) 68
cell survival - drug effects (67) 67
drug synergism (66) 66
signal transduction - drug effects (66) 66
xenograft model antitumor assays (66) 66
medicine & public health (65) 65
mutation (65) 65
tumors (65) 65
bridged bicyclo compounds - therapeutic use (64) 64
medicine (64) 64
physical sciences (64) 64
receptors, metabotropic glutamate - agonists (64) 64
science (62) 62
structure-activity relationship (62) 62
cells, cultured (61) 61
pharmacology (61) 61
clinical trials (60) 60
sulfonamides - administration & dosage (60) 60
adolescent (59) 59
boron compounds - therapeutic use (58) 58
bridged bicyclo compounds - pharmacology (58) 58
aged, 80 and over (57) 57
medical research (57) 57
dermatology (56) 56
norcantharidin (56) 56
receptors, nicotinic - metabolism (56) 56
signal transduction (56) 56
studies (56) 56
bridged bicyclo compounds, heterocyclic - chemical synthesis (52) 52
inhibitors (51) 51
physiological aspects (51) 51
chemistry, medicinal (49) 49
gene expression (49) 49
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1486) 1486
Japanese (16) 16
Russian (14) 14
German (12) 12
Italian (11) 11
Chinese (6) 6
Danish (3) 3
French (3) 3
Spanish (3) 3
Hungarian (2) 2
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 10/2017, Volume 31, Issue 10, pp. 2075 - 2084
Although the BTK inhibitor ibrutinib has transformed the management of patients with chronic lymphocytic leukemia (CLL), it does not induce substantial... 
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Peptide Fragments | Pyrazoles - therapeutic use | Proto-Oncogene Proteins c-bcl-2 - physiology | Apoptosis - drug effects | Humans | Neoplasm Proteins - physiology | Pyrazines - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - agonists | Neoplasm Proteins - antagonists & inhibitors | Pyrazines - therapeutic use | Molecular Targeted Therapy | Benzamides - administration & dosage | Benzamides - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sulfonamides - agonists | Benzamides - pharmacology | Proto-Oncogene Proteins | Pyrazoles - pharmacology | Pyrimidines - administration & dosage | Bcl-2-Like Protein 11 - genetics | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Clinical Trials as Topic | Mitochondria - drug effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Bcl-2-Like Protein 11 - biosynthesis | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Protein Kinase Inhibitors - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazines - pharmacology | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Drug Screening Assays, Antitumor | Protein-Tyrosine Kinases - antagonists & inhibitors | Enzymes | Chronic lymphocytic leukemia | Care and treatment | Development and progression | Genetic aspects | Regulation | Drug resistance | Health aspects | Killing | Tyrosine | Drugs | Medical research | Chronic lymphatic leukemia | Bcl-2 protein | Leukemia | Clinical trials | Priming | Lymphatic leukemia | Patients | Bruton's tyrosine kinase | Mitochondria | Inhibitors | Cell death | Sensitivity enhancement | Inhibition | Pretreatment | Protein-tyrosine kinase | BIM protein | Apoptosis | Index Medicus | ibrutinib | BCL-2 | mitochondrial priming | acalabrutinib (ACP-196) | BTK | venetoclax | BH3 profiling
Journal Article
Blood, ISSN 1528-0020, 11/2017, Volume 130, Issue 22, pp. 2392 - 2400
Journal Article
Blood, ISSN 1528-0020, 10/2018, Volume 132, Issue 15, pp. 1568 - 1572
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 09/2016, Volume 75, Issue 3, pp. 494 - 503.e6
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
... leukemia cells; therefore, BCL2 represents a rational therapeutic target. 10 – 12 Venetoclax, an orally administered, highly selective, potent BCL2 inhibitor, 13 acts... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Evidence-based medicine | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 8/2010, Volume 107, Issue 32, pp. 14309 - 14314
Journal Article
Nature chemical biology, ISSN 1552-4469, 11/2010, Volume 7, Issue 1, pp. 41 - 50
Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and molecular mechanisms by which Btk mediates inflammation are poorly understood... 
Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Tumor Necrosis Factor-alpha - metabolism | Arthritis, Experimental - drug therapy | Autoantibodies - metabolism | Protein-Tyrosine Kinases - therapeutic use | Arthritis, Experimental - metabolism | Arthritis, Rheumatoid - metabolism | Protein-Tyrosine Kinases - pharmacology | Protein Kinase Inhibitors - chemistry | Benzamides - therapeutic use | Arthritis, Rheumatoid - drug therapy | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Interleukin-1beta - metabolism | Myeloid Cells - immunology | Protein-Tyrosine Kinases - chemistry | Tumor Necrosis Factor-alpha - immunology | Myeloid Cells - drug effects | Benzamides - pharmacology | Phosphorylation - drug effects | Interleukin-6 - metabolism | B-Lymphocytes - metabolism | Benzamides - chemistry | Bridged Bicyclo Compounds, Heterocyclic - chemistry | Interleukin-1beta - immunology | Arthritis, Experimental - immunology | Enzyme Activation - drug effects | B-Lymphocytes - drug effects | Autoantibodies - immunology | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | B-Lymphocytes - immunology | Protein Kinase Inhibitors - therapeutic use | Interleukin-6 - immunology | Myeloid Cells - metabolism | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Arthritis, Rheumatoid - immunology | Arthritis | Biochemistry | Inhibitor drugs | Kinases | Binding sites | Index Medicus
Journal Article
Physical chemistry chemical physics : PCCP, ISSN 1463-9084, 2018, Volume 20, Issue 9, pp. 6606 - 6616
Journal Article
Journal Article